OncoMatch/Clinical Trials/NCT06810583
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Is NCT06810583 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Dalbavancin and Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for leukemia.
Treatment: Dalbavancin · Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) — This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: \- To estimate the rate of bacterial bloodstream infection in pediatric patients with AML or relapsed ALL undergoing chemotherapy receiving dalbavancin-based prophylaxis Secondary objectives: * To describe the population pharmacokinetics of every 28 days dalbavancin up to 12 weeks in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the tolerability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To describe the acceptability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy * To estimate the rates of likely bacterial infections, Clostridioides difficile infection, and febrile neutropenia in pediatric patients receiving dalbavancin-based prophylaxis
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Lab requirements
Blood counts
treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml)
Kidney function
Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2 [excluded]
Liver function
Alkaline phosphatase, alanine transferase or total bilirubin ≥ 3x upper limit of normal for age [excluded]
Cardiac function
Diagnosed with long QT syndrome [excluded]
treatment is expected to cause prolonged (> 7 days) severe neutropenia (ANC < 500/ml); Alkaline phosphatase, alanine transferase or total bilirubin ≥ 3x upper limit of normal for age; Estimated glomerular filtration rate (EGFR) <30 mL/minute/1.73 m2; Diagnosed with long QT syndrome
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify